Portfolio & partnerships
Published:
08.12.2020
Novel biologics and biosimilars pipeline and portfolio
Polpharma Biologics has its own pipeline of biosimilar and novel therapeutics for out-licensing. We are focused on advancing and expanding our product portfolio to increase patient access to these much-needed therapies and are open to partnering with other organizations to co-develop or commercialize our biosimilars or novel therapeutics.